Unlocking the STRIPAK Complex and Fusion-Driven Oncogenesis: High-Purity Reagents for Striatin-Targeted Therapeutics
As a core scaffolding subunit of the STRIPAK (Striatin-Interacting Phosphatase and Kinase) complex, STRN (Striatin) regulates critical signaling nodes in cancer progression, including MAP4K family kinase deactivation and PP2A phosphatase activity. Beyond its complex function, STRN also drives oncogenesis through gene fusions (e.g., STRN-ALK, STRN-NTRK1) found in thyroid cancer, NSCLC, and sarcomas. With emerging interest in Targeted Protein Degradation (TPD), molecular glue strategies, and precision kinase inhibition, STRN represents a novel therapeutic axis for both scaffold disruption and fusion-positive malignancies. TarMart provides sequence-verified recombinant proteins, viral delivery systems, and control reagents engineered to support PPI assays, complex assembly studies, degradation screening, and fusion-specific drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STRN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STRN Full-Length / WD40 Domain Recombinant Protein (>95% purity, HEK293 expressed, Endotoxin <1EU/ug); STRN-ALK Fusion Protein (sequence-verified for clinical breakpoints) | View STRN Products |
| Gene Delivery | STRN Promise-ORF Lentivirus (full-length ORF for stable cell lines, native complex formation) | View STRN Products |
| Benchmark Ab | Anti-STRN (N-Terminal Calmodulin-Binding Domain) Recombinant Antibody (high-specificity control for WB/IHC) | View STRN Products |
| Validator | STRN siRNA Set (for knockdown verification and specificity controls) | View STRN Products |
| Complex Partner A | PPP2R1A (PP2A Scaffold Subunit) — for STRIPAK complex assembly studies | View PPP2R1A Products |
| Complex Partner B | MOB4 (Phosphatase Activator) — critical STRIPAK component for functional assays | View MOB4 Products |
| Complex Partner C | STRIP1 (Striatin-Interacting Protein) — regulatory subunit for complex integrity validation | View STRIP1 Products |
| Related Target A | ALK (frequent fusion partner in thyroid/lung cancers; includes mutant forms for selectivity panels) | View ALK Products |
| Related Target B | NTRK1 (emerging fusion partner in solid tumors) | View NTRK1 Products |
| Related Target C | PPP2CA (core catalytic subunit of PP2A, recruited by STRN) | View PPP2CA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| STRIPAK Complex Assembly (PPI Networks) | Full-length STRN with intact WD40 repeats; HEK293 expressed for native folding; Suitable for Co-IP and SPR analysis |
| Scaffold Function Disruption (TPD Screening) | High-concentration STRN protein (>95% purity) for AlphaScreen/TR-FRET degradation assays; Stable lentivirus for cellular turnover studies |
| Fusion Protein Modeling (STRN-ALK/NTRK1) | Sequence-verified recombinant proteins engineered for exact clinical fusion breakpoints; Theoretical MW annotated |
| Endogenous Complex Competition | siRNA validation sets included for specificity confirmation; orthologous protein variants available |
| Phosphatase Activity Regulation | Co-recombinant PPP2R1A available for holoenzyme reconstitution assays |
| Intracellular Target Engagement | Lentiviral ORF delivery for stable cell line generation; preserves native conformation and PTMs in situ |
| Lack of Specific Controls | Benchmark recombinant antibody included for reproducible detection; validated siRNA for genetic knockdown |
Live STRN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The STRN therapeutic landscape is transitioning from observational cancer biology to targeted intervention, with two parallel tracks: scaffold disruption and fusion-targeted therapy. On one hand, wild-type STRN’s role in the STRIPAK complex makes it an attractive target for TPD and molecular glue strategies, aiming to ablate the scaffolding function that regulates MAP4K and PP2A signaling. On the other hand, oncogenic fusions (especially STRN-ALK and STRN-NTRK1) create druggable kinase domains that are constitutively activated via STRN-mediated dimerization. First-generation TKIs (e.g., crizotinib, lorlatinib, larotrectinib) show clinical activity in fusion-positive thyroid and lung cancers, but acquired resistance mutations (e.g., ALK G1202R) drive the need for next-generation inhibitors and degradation modalities.
"The race for STRN therapeutics is intensifying. For the scaffold branch, major players are shifting from traditional enzymatic inhibition to scaffold disruption via PROTACs and molecular glues. For the fusion branch, overcoming resistance requires selective next-generation TKIs and dual-mechanism degraders that eliminate both kinase activity and scaffold interaction."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue / PROTAC | Emerging Academic/Biotech | Colorectal Cancer, Prostate Cancer, Refractory Solid Tumors | Intact STRN Protein for Ternary Complex Formation; Full-length, properly folded STRN (>95%) |
| Small Molecule (TKI) | Pfizer, Roche, Novartis | NSCLC, Thyroid Cancer, Sarcomas | STRN-ALK/NTRK1 Fusion Proteins (WT and mutant) for selectivity vs. WT ALK |
| STRIPAK Complex Disruptor | Preclinical Biotech | Solid Tumors, Cardiac Hypertrophy | Full-length STRN + PP2A Holoenzyme Reconstitution (HEK293 expressed, endotoxin-controlled) |
| Genetic Screens (CRISPR/RNAi) | Functional Genomics Consortia | Resistance Mechanisms, Synthetic Lethality | Lentivirus for stable knock-in/overexpression; Validated siRNA sets |
| Peptide Disruptors | Early Discovery Programs | Solid Tumors | STRIPAK Complex PPI Assays (Need STRN + PPP2R1A + MOB4 combination sets) |